Emisphere Technologies and Novo Nordisk have amended Oral GLP-1 receptor agonist development and license agreement. Nordisk's GLP-1 receptor agonists have shown to leverage Emisphere's Eligen technology to treat type 2 diabetes. As per the terms of the amended deal, Emisphere will receive $10 million as a prepayment of development milestone payments from Novo Nordisk.

Emisphere is eligible for product development and sales milestone payments along with potential future royalty payments. Both the companies initially signed the licensing deal in 2008. At present, Phase I trials for its Oral GLP-1 product candidate are being conducted by Novo Nordisk.